AI Article Synopsis

  • A 34-year-old woman experienced abdominal pain, jaundice, and itching, leading to an ERCP procedure that initially appeared normal.
  • Using a balloon catheter for cholangiography revealed irregularities suggestive of early-stage primary sclerosing cholangitis (PSC), a chronic liver condition affecting bile ducts.
  • The standard ERCP typically shows characteristic findings for PSC, but early diagnosis can be tricky; the balloon catheter technique may enhance detection of early changes in the bile ducts.

Article Abstract

A 34-year-old woman was admitted to our clinic with abdominal pain, jaundice and pruritus. Endoscopic retrograde cholangiopancreatography was performed for cholestasis. Endoscopic retrograde cholangiopancreatography (ERCP) was judged as normal, after a standard ERCP cannula was used for the cholangiogram. However, marked canalicular irregularities were identified in cholangiography when pressurized contrast agent was administrated via balloon catheter. This cholangiographic view was thought to reveal an early-stage alteration of sclerosing cholangitis. Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by destruction and fibrosis of the bile ducts. The diagnosis of PSC is based on typical cholangiographic findings, supported by nonspecific clinical signs and symptoms, cholestatic liver biochemical tests, and liver biopsy. Cholangiography is considered to be the gold standard for the diagnosis of PSC. The diagnosis is easy when diffuse multifocal biliary strictures, the hallmarks of the disease, resulting in a 'beaded' appearance on ERCP is detected. However, it may reveal a normal image in an early stage of the disease when bile duct changings are not prominent. We think that balloon catheter ERCP appears to facilitate the diagnosis of early-stage primary sclerosing cholangitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988889PMC
http://dx.doi.org/10.1159/000272408DOI Listing

Publication Analysis

Top Keywords

sclerosing cholangitis
16
balloon catheter
12
primary sclerosing
12
endoscopic retrograde
12
retrograde cholangiopancreatography
12
early-stage primary
8
cholestatic liver
8
diagnosis psc
8
diagnostic endoscopic
4
endoscopic balloon
4

Similar Publications

Case report of a patient with a duodenal ulcer, initially treated with sclerosing agents, as is common practice for most bleeding ulcers. However, the evolution following this treatment is unusual. The patient developed secondary ischemic cholangitis, leading to extensive aerobilia and secondary portal pneumatosis, accompanied by inflammatory changes in the head of the pancreas.

View Article and Find Full Text PDF

Gallbladder-derived retinoic acid signalling drives reconstruction of the damaged intrahepatic biliary ducts.

Nat Cell Biol

January 2025

State Key laboratory of Genetic Engineering, School of Life Sciences, Liver Cancer Institute of Zhongshan Hospital, Fudan University, Shanghai, China.

Severe damage to the intrahepatic biliary duct (IHBD) network occurs in multiple human advanced cholangiopathies, such as primary sclerosing cholangitis, biliary atresia and end-stage primary biliary cholangitis. Whether and how a severely damaged IHBD network could reconstruct has remained unclear. Here we show that, although the gallbladder is not directly connected to the IHBD, there is a common hepatic duct (CHD) in between, and severe damage to the IHBD network induces migration of gallbladder smooth muscle cells (SMCs) to coat the CHD in mouse and zebrafish models.

View Article and Find Full Text PDF

Hepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: A retrospective analysis.

Saudi Med J

January 2025

From the Department of Surgery (Aljiffry, Dahal, Baeisa, Alzahrani, Saleem, Alshahrany), from the Department of Medicine (Hijji, Alsahafi, Alghamdi, Mosli), from the Faculty of Medicine (Aljiffry, Daha, Baeisa, Alzahrani, Alshahrany, Hijji, Alsahafi, Saleem, Alghamdi, Mosli), King Abdulaziz University, from the Inflammatory Bowel Disease Research Group (Alsahafi, Mosli), and from the Gastrointestinal Oncology Unit (Saleem, Alghamdi), King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.

Objectives: To evaluate the features and frequency of hepatobiliary diseases in individuals with Inflammatory bowel disease (IBD).

Methods: This retrospective study included all IBD patients at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. The primary focus was on the prevalence of hepatobiliary diseases, such as primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and others.

View Article and Find Full Text PDF

Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses.

Therap Adv Gastroenterol

January 2025

Department of Gastroenterology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.

Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), can affect the hepatobiliary system and pancreas, substantially impacting the life quality of patients.

Objectives: To evaluate the quality of evidence and comprehensively assess the validity of associations of IBD with hepatobiliary and pancreatic diseases.

Design: We performed an umbrella review of existing meta-analyses in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) recommendations.

View Article and Find Full Text PDF

Management of primary sclerosing cholangitis: Current state-of-the-art.

Hepatol Commun

December 2024

Division of Gastroenterology and Hepatology, Department of Medicine, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Article Synopsis
  • Primary sclerosing cholangitis is a chronic liver condition associated with inflammation and fibrosis of bile ducts, often linked to inflammatory bowel disease and increases the risk of cancer.
  • Current treatments mainly offer supportive care, as there are no effective medical therapies available and liver transplantation can prolong life but does not cure the disease.
  • Research is ongoing into new therapies aimed at slowing disease progression and alleviating symptoms, with improved trial designs focused on selecting appropriate patients and using better outcome measures to assess treatment effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!